Logo image of SGMT

SAGIMET BIOSCIENCES INC-A (SGMT) Stock Fundamental Analysis

USA - NASDAQ:SGMT - US7867001049 - Common Stock

7.29 USD
+0.13 (+1.82%)
Last: 10/3/2025, 8:03:27 PM
7.15 USD
-0.14 (-1.92%)
After Hours: 10/3/2025, 8:03:27 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SGMT. SGMT was compared to 536 industry peers in the Biotechnology industry. While SGMT has a great health rating, there are worries on its profitability. SGMT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SGMT had negative earnings in the past year.
SGMT had a negative operating cash flow in the past year.
In the past 5 years SGMT always reported negative net income.
SGMT had a negative operating cash flow in each of the past 5 years.
SGMT Yearly Net Income VS EBIT VS OCF VS FCFSGMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SGMT has a Return On Assets of -28.43%. This is in the better half of the industry: SGMT outperforms 68.66% of its industry peers.
SGMT has a better Return On Equity (-29.25%) than 77.80% of its industry peers.
Industry RankSector Rank
ROA -28.43%
ROE -29.25%
ROIC N/A
ROA(3y)-49.87%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
SGMT Yearly ROA, ROE, ROICSGMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SGMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMT Yearly Profit, Operating, Gross MarginsSGMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, SGMT has more shares outstanding
SGMT has more shares outstanding than it did 5 years ago.
SGMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMT Yearly Shares OutstandingSGMT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SGMT Yearly Total Debt VS Total AssetsSGMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SGMT has an Altman-Z score of 38.20. This indicates that SGMT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 38.20, SGMT belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
SGMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.2
ROIC/WACCN/A
WACCN/A
SGMT Yearly LT Debt VS Equity VS FCFSGMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

SGMT has a Current Ratio of 34.30. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SGMT (34.30) is better than 97.95% of its industry peers.
SGMT has a Quick Ratio of 34.30. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
SGMT has a better Quick ratio (34.30) than 97.95% of its industry peers.
Industry RankSector Rank
Current Ratio 34.3
Quick Ratio 34.3
SGMT Yearly Current Assets VS Current LiabilitesSGMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

SGMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.66%.
The Revenue for SGMT has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-13.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.01% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-28%
EPS Next 2Y-20.84%
EPS Next 3Y-15.14%
EPS Next 5Y3.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SGMT Yearly Revenue VS EstimatesSGMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SGMT Yearly EPS VS EstimatesSGMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMT Price Earnings VS Forward Price EarningsSGMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMT Per share dataSGMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as SGMT's earnings are expected to decrease with -15.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.84%
EPS Next 3Y-15.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGIMET BIOSCIENCES INC-A

NASDAQ:SGMT (10/3/2025, 8:03:27 PM)

After market: 7.15 -0.14 (-1.92%)

7.29

+0.13 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-14 2025-11-14/bmo
Inst Owners29.21%
Inst Owner Change-0.11%
Ins Owners1.08%
Ins Owner Change-1.05%
Market Cap302.83M
Analysts85.33
Price Target26.27 (260.36%)
Short Float %8.61%
Short Ratio4.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.37%
Min EPS beat(2)-8.35%
Max EPS beat(2)21.1%
EPS beat(4)3
Avg EPS beat(4)20.49%
Min EPS beat(4)-8.35%
Max EPS beat(4)43.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.09%
EPS NY rev (3m)18.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-2.09
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0
BVpS3.75
TBVpS3.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.43%
ROE -29.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.87%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 34.3
Quick Ratio 34.3
Altman-Z 38.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
EPS Next Y-28%
EPS Next 2Y-20.84%
EPS Next 3Y-15.14%
EPS Next 5Y3.01%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-77.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.72%
EBIT Next 3Y-37.85%
EBIT Next 5YN/A
FCF growth 1Y-78.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.55%
OCF growth 3YN/A
OCF growth 5YN/A